Drugs / AZ compound
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02605616 | Nov 2015 → Sep 2019 | NAFLD1, metabolic dysfunction-associated steatohepatitis | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZ compound | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02605616 ↗ |